Core Insights - Jiangsu Province's Science and Technology Department has announced the first batch of major provincial science and technology projects for 2025, focusing on "Innovative Biopharmaceuticals" [1] - Suzhou leads the province with 11 selected projects, accounting for 58% of the total proposed projects, highlighting its strength and innovation in the biopharmaceutical sector [1] Project Distribution - The selected projects in Suzhou show a significant concentration, with 8 projects from Suzhou Industrial Park, and 1 each from Zhangjiagang, Suzhou High-tech Zone, and Suzhou University, indicating a cluster advantage in the biopharmaceutical industry [1] - Research directions include cancer treatment, neurological diseases, infection control, innovative drug delivery, and core industrial equipment, aiming to address clinical treatment challenges and industry development bottlenecks [1] Focus on Clinical Needs - Several projects target unmet clinical needs, focusing on cutting-edge therapies, such as the development of "safe and efficient personalized mRNA tumor vaccines" and "targeted KRAS mutation-enhanced TCR-T cell therapy drugs," providing new treatment solutions for malignant tumors, neurodegenerative diseases, and infectious diseases [1] Technological Advancements - Projects like "novel inhalation delivery system for nucleic acid drugs targeting major lung diseases" and "efficient and precise targeted nucleic acid delivery platform technology development" focus on enhancing the efficiency and industrialization of biopharmaceutical R&D across the entire drug development chain [2] - Significant progress has been made in key equipment and platform construction for biopharmaceutical R&D, with projects such as "AI-assisted design of new biopharmaceutical chromatography consumables and big data platform for separation and purification" and "high-parameter high-purity spectral flow cytometry analysis and sorting instruments" aimed at achieving self-controllable core R&D equipment and materials [2] Recognition and Future Potential - The outstanding performance of Suzhou in the provincial science and technology major projects reflects a high recognition of its current biopharmaceutical R&D capabilities and showcases its immense innovation potential in cutting-edge biopharmaceutical technologies [2] - The implementation and advancement of these projects are expected to significantly promote innovation breakthroughs and clinical transformation processes in biopharmaceutical technologies, continuously injecting new momentum into the treatment of major diseases and the development of the biopharmaceutical industry [2]

Core Viewpoint - The company is on track to complete the first patient dosing of its mRNA tumor vaccine within this year, focusing on glioblastoma and rhabdomyosarcoma indications [2] Company Progress - The company confirmed that the development of the mRNA vaccine is proceeding as planned and that the progress is in line with expectations [2] - Investors are encouraged to follow the company's official updates for further information on the vaccine's development [2]

Core Viewpoint - The collaboration between 思路迪医药 and 楷拓生物 aims to enhance the development of mRNA-based therapies by leveraging their respective strengths in AI-driven mRNA research and large-scale mRNA production [1] Group 1: Strategic Collaboration - 思路迪医药 has entered into a strategic cooperation framework agreement with 楷拓生物, focusing on the integration of their technologies in mRNA research and delivery systems [1] - The partnership will utilize 思路迪医药's proprietary AI+mRNA research platform and lipid nanoparticle (LNP) delivery system alongside 楷拓生物's expertise in mRNA production [1] Group 2: Technological Advancements - 思路迪医药 has established a globally recognized mRNA technology platform and LNP delivery system, which are crucial for the development of innovative therapies [1] - The mRNA technology platform includes a multi-module tumor vaccine analysis system (3D-PreciseAg) that supports extensive antigen multi-omics analysis and selection of tumor antigens [1] - The AI-enhanced LNP delivery technology platform allows for the screening of thousands of compounds, resulting in the synthesis of various LNP products tailored for different delivery scenarios, improving the efficiency and targeting of mRNA tumor vaccines and immune cell therapies [1]

Core Viewpoint - The announcement highlights a strategic cooperation agreement between Sillodic Pharmaceuticals and Kaito Bio, focusing on the development of mRNA-based therapies utilizing Sillodic's proprietary AI+mRNA research platform and lipid nanoparticle delivery system [1] Group 1: Strategic Cooperation - Sillodic Pharmaceuticals entered into a strategic cooperation framework agreement with Kaito Bio on August 20, 2025 [1] - The collaboration aims to leverage Sillodic's self-developed AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP) alongside Kaito Bio's expertise in large-scale mRNA production [1] - The partnership will enhance cooperation in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, with specific implementations to follow in formal agreements [1] Group 2: Technological Advancements - Sillodic Pharmaceuticals has established a globally recognized mRNA technology platform and LNP delivery system [1] - The mRNA technology platform is built on advanced AI technology, featuring a multi-module tumor vaccine analysis platform (3D-PreciseAg) that supports extensive antigen multi-omics analysis and optimal tumor antigen selection [1] - The AI-enhanced LNP delivery technology platform allows for the screening of thousands of compounds through AI algorithms, resulting in various LNP products that improve delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK therapies while significantly reducing toxicity [1]

Group 1 - The core viewpoint of the news is that Sidodi Pharmaceutical has entered into a strategic cooperation framework agreement with Kaito Bio to enhance their collaboration in the mRNA field, leveraging their respective strengths in AI+mRNA research and large-scale mRNA production [1] - The collaboration will focus on targeted LNP delivery, tumor vaccines, and in vivo CAR-T/NK therapies, indicating a significant step in Sidodi Pharmaceutical's commitment to mRNA research and development [1] - This partnership aims to provide robust capacity support for the clinical development and future commercialization of innovative therapies based on mRNA-LNP technology [1] Group 2 - Sidodi Pharmaceutical has established a globally recognized mRNA technology platform and LNP delivery system, which is built on advanced AI technology [2] - The mRNA technology platform includes a multi-module tumor vaccine analysis platform (3D-PreciseAg) that supports extensive antigen multi-omics analysis and the selection of tumor antigens [2] - The company possesses an AI-enhanced LNP delivery technology platform that utilizes AI algorithms to screen thousands of compounds, improving the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK therapies while significantly reducing toxicity [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 3D Medicines Inc. 思路迪医药股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1244） 本公司欣然宣布，思路迪醫藥於2025年8月20日與楷拓生物訂立戰略合作框架協 議（「該協議」）。 根據該協議，雙方將基於思路迪醫藥的自研具有自有知識產權的AI+mRNA研發 平台和脂質體遞送系統(3D-LNP)，與楷拓生物的mRNA規模化生產優勢和經驗， 深化靶向LNP遞送(tLNP)、腫瘤疫苗、in vivo CAR-T/NK等領域的合作。具體實 施將依據後續正式協議落實。此次合作標誌着思路迪醫藥正不斷加速布局mRNA 領域研究，為基於mRNA-LNP技術的創新療法產品後續臨床開發以及未來商業化 提供堅實的產能保障。 思路迪醫藥目前已建立起擁有全球自主知識產權的mRNA技術平台及LNP遞送系 統平台。該mRNA技術平台是基於目前先進的AI技術構建的多模塊腫瘤疫苗分析 平台(3D-Pre ...

Core Viewpoint - Genting Yongying (01952) has seen a stock price increase of over 3%, currently trading at 72.05 HKD with a transaction volume of 231 million HKD, following its strategic investment in Tianjing Bio [1] Group 1: Strategic Investment - Genting Yongying participated in Tianjing Bio's capital increase, acquiring new shares at a price of 1.95 USD per ADS, totaling approximately 30.9 million USD, making it the largest single shareholder of Tianjing Bio [1] - This strategic investment allows Genting Yongying to leverage Tianjing Bio's differentiated 4-1BB platform, dual antibody pipeline, and overseas clinical translation capabilities, creating synergies with its existing mRNA tumor vaccine portfolio [1] Group 2: Tianjing Bio's Pipeline - Tianjing Bio has a differentiated pipeline for tumor-targeted/immunotherapy, including Givastomig (Claudin18.2/4-1BB dual antibody) and Ragistomig (PD-L1/4-1BB dual antibody) [1] - Givastomig is currently being explored in first-line gastric cancer treatment in combination with O drug and chemotherapy, showing data superior to current first-line gastric cancer standard therapies in a Phase Ib study in the U.S. [1] - Ragistomig features a unique molecular design that binds PD-L1 only in the tumor microenvironment and activates 4-1BB, with Phase I data indicating an overall response rate (ORR) and disease control rate (DCR) superior to competing products targeting the same pathway [1]

Core Viewpoint - CloudTop New Horizon (01952) has increased by over 3%, currently trading at 72.05 HKD with a transaction volume of 231 million HKD, following its strategic investment in Tianjing Bio [1] Group 1: Strategic Investment - CloudTop New Horizon has participated in Tianjing Bio's capital increase, acquiring new shares at a price of 1.95 USD per ADS, totaling approximately 30.9 million USD, making it the largest single shareholder of Tianjing Bio [1] - The investment is expected to leverage Tianjing's differentiated 4-1BB platform, dual antibody pipeline, and overseas clinical translation capabilities, creating synergies with CloudTop's existing mRNA tumor vaccine portfolio [1] Group 2: Product Pipeline - Tianjing Bio possesses a differentiated pipeline of tumor-targeted/immunotherapies, including Givastomig (Claudin18.2/4-1BB dual antibody) and Ragistomig (PD-L1/4-1BB dual antibody) [1] - Givastomig is currently being explored in first-line gastric cancer treatment in combination with O drug and chemotherapy, showing superior data compared to current standard therapies in the U.S. Phase Ib study [1] - Ragistomig features a unique molecular design that binds PD-L1 only in the tumor microenvironment and activates 4-1BB, with Phase I data indicating better ORR and DCR compared to competing products targeting the same pathway [1]

Core Viewpoint - CloudTop New Horizon (01952) has seen a stock increase of over 3%, currently trading at 72.05 HKD with a transaction volume of 231 million HKD, following its strategic investment in Tianjing Bio [1] Group 1: Strategic Investment - CloudTop New Horizon has participated in Tianjing Bio's capital increase, acquiring new shares at a price of 1.95 USD per ADS, totaling approximately 30.9 million USD, making it the largest single shareholder [1] - This strategic investment allows CloudTop New Horizon to leverage Tianjing's differentiated 4-1BB platform, dual antibody pipeline, and overseas clinical translation capabilities, creating synergies with its existing mRNA tumor vaccine portfolio [1] Group 2: Tianjing Bio's Pipeline - Tianjing Bio possesses a differentiated pipeline of tumor-targeted/immunotherapies, including Givastomig (Claudin18.2/4-1BB dual antibody) and Ragistomig (PD-L1/4-1BB dual antibody) [1] - Givastomig is currently being explored in first-line gastric cancer treatment in combination with O drug and chemotherapy, showing superior data compared to current standard therapies in the U.S. Phase Ib study [1] - Ragistomig features a unique molecular design that selectively binds to PD-L1 in the tumor microenvironment and activates 4-1BB, with Phase I data indicating better overall response rate (ORR) and disease control rate (DCR) compared to competing products targeting the same pathway [1]

Group 1 - BioNTech's research on mRNA neoantigen vaccines shows potential in treating pancreatic cancer by inducing long-lived CD8+ T cell responses, offering new hope for cancer immunotherapy [1] - The challenge of tumor recurrence and metastasis remains significant in clinical treatment, highlighting the importance of mRNA technology in immune response [1] - Cloud Health's CEO discusses how mRNA technology stimulates T and B cells to create specific immune responses against tumor cells, forming immune memory to reduce recurrence risk [1] Group 2 - mRNA technology shifts drug development from "molecular screening" to "information design," transforming the human body into a smart factory for protein drug production [2] - Despite its advantages, the delivery system poses a major barrier for mRNA technology, as synthesized mRNA is prone to degradation when entering the human body [2] - Cloud Health has made breakthroughs in delivery technology, establishing a proprietary LNP (lipid nanoparticle) delivery platform with patents in ionizable and stealth lipids [2] Group 3 - The third-generation AI algorithm significantly enhances target protein expression levels, enabling Cloud Health to advance mRNA tumor drug development [3] - EVM16 is Cloud Health's first personalized mRNA tumor vaccine entering clinical stages, with the first patient dosing completed in March 2025 [3] - EVM14 is a universal therapeutic vaccine targeting five tumor-related antigens, intended for the treatment of squamous cell carcinoma [3]